Prostate-specific Antigen as Surrogate for Characterizing Prostate Cancer Subgroups

Author： Sandblom G. Holmberg L. Damber J.-E. Hugosson J. Johansson J.-E. Lundgren R. Mattsson E. Nilsson J. Varenhorst E.

Publisher： Informa Healthcare

ISSN： 0036-5599

Source： Scandinavian Journal of Urology and Nephrology, Vol.36, Iss.2, 2002-04, pp. : 106-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of prostate-specific antigen screening on prostate cancer

By Zincke H.

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 783-783

Elsevier

Access to resources Recommend Favorite

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

By Zietman A.L. Dallow K.C. McManus P.A. Heney N.M. Shipley W.U.

Urology, Vol. 47, Iss. 2, 1996-02 ,pp. : 236-239

Elsevier

Access to resources Recommend Favorite

Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity

By Carter H.B. Pearson J.D. Waclawiw Z. Metter E.J. Chan D.W. Guess H.A. Walsh P.C.

Urology, Vol. 45, Iss. 4, 1995-04 ,pp. : 591-596

Elsevier

Access to resources Recommend Favorite

Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer

By Chen Y.-T. Luderer A.A. Thiel R.P. Carlson G. Cuny C.L. Soriano T.F.

Urology, Vol. 47, Iss. 4, 1996-04 ,pp. : 518-524

Elsevier

Access to resources Recommend Favorite

Methodological and clinical comparison of the ACS prostate-specific antigen assay and the tandem-E prostate-specific antigen assay in prostate cancer

By Schambeck C.M. Schmeller N. Stieber P. Jansen H.-M. Pahl H. Schneider W. Fateh-Moghadam A.

Urology, Vol. 46, Iss. 2, 1995-08 ,pp. : 195-199

Elsevier

Access to resources Recommend Favorite